Tilray Brands/$TLRY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tilray Brands
Tilray is as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. The company portfolio includes brand such as Sweet Water Brewing, Montauk Brewing, Brew Dog, Shock Top, 10 Barrell, Breckenridge Brewery, Blue Point Brewing, Breckenridge Distillery, Revolver, Terrapin, Broken Coast, Good Supply, Redecan, Solei, Tilray, ARX, XMG, Manitoba Harvest and Hi-Ball. The company has four segment Beverage, Cannabis, Distribution and Wellness. The majority of the revenue is generated from Distribution business which encompasses the purchase and resale of pharmaceuticals products to customers.
- Ticker
- $TLRY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,595
- Headquarters
- Leamington, Canada
- Website
- www.tilray.com
Tilray Brands Metrics
BasicAdvanced
$387M
-
-$1.38
1.92
-
Price and volume
Market cap
$387M
Beta
1.92
52-week high
$15.70
52-week low
$2.62
Average daily volume
4.2M
Financial strength
Current ratio
1.875
Quick ratio
0.949
Long term debt to equity
0.172
Total debt to equity
0.231
Interest coverage (TTM)
-1.90%
Profitability
EBITDA (TTM)
12.691
Gross margin (TTM)
29.35%
Net profit margin (TTM)
-17.05%
Operating margin (TTM)
-6.02%
Effective tax rate (TTM)
-16.81%
Revenue per employee (TTM)
$270,000
Management effectiveness
Return on assets (TTM)
-1.64%
Return on equity (TTM)
-9.38%
Valuation
Price to revenue (TTM)
0.325
Price to book
0.23
Price to tangible book (TTM)
0.46
Price to free cash flow (TTM)
-2.637
Free cash flow yield (TTM)
-37.93%
Free cash flow per share (TTM)
-1.001
Growth
Revenue change (TTM)
15.93%
Earnings per share change (TTM)
-93.98%
3-year revenue growth (CAGR)
13.95%
10-year revenue growth (CAGR)
60.38%
3-year earnings per share growth (CAGR)
-60.50%
10-year earnings per share growth (CAGR)
21.33%
What the Analysts think about Tilray Brands
Analyst ratings (Buy, Hold, Sell) for Tilray Brands stock.
Analyst projections of the future price of Tilray Brands stock.
Bulls say / Bears say
First-quarter revenue rose 23% to a record $257.1 million, while gross profit increased 35% and gross margin widened to 30%. That suggests the larger, more diversified business is generating stronger gross profit as it grows. (Tilray Brands)
Beverage revenue jumped 82% to $101.5 million, and management said BrewDog was profitable in the quarter. The acquisition is already adding scale and earnings contribution to Tilray’s beverage business. (Tilray Brands, The Globe and Mail)
International cannabis revenue grew 21% to $16.2 million, with higher patient demand in Germany and the contribution from UK clinic and pharmacy business Lyphe. This gives Tilray a growing foothold beyond its pressured Canadian market. (Tilray Brands)
Cannabis revenue fell 13% year on year to $56.1 million, and cannabis gross profit also declined. Growth in the wider group is not yet translating into a recovery in Tilray’s core cannabis business. (Tilray Brands)
Tilray recorded a $40 million net loss and used $16.5 million of cash in operating activities; adjusted EBITDA also fell to $9.2 million from $10.2 million. Continued cash outflow and weaker adjusted earnings raise questions about how reliably growth can produce profits. (SEC)
Management said Tilray’s legacy US craft beverage business would have seen lower revenue without BrewDog, as the company cuts brands and product lines. That suggests the sharp beverage growth depends heavily on the acquisition rather than a recovery in the existing business. (The Globe and Mail)
Data summarised monthly by Lightyear AI. Last updated on 12 Oct 2026.
Tilray Brands Financial Performance
Revenues and expenses
Tilray Brands Earnings Performance
Company profitability
Upcoming events
No upcoming events
Tilray Brands News
AllArticlesVideos
Funds containing Tilray Brands
Fund name | Fund size | $TLRY weighting |
|---|---|---|
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.01% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.